Needham Maintains Buy on Cartesian Therapeutics, Lowers Price Target to $40
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Needham analyst Gil Blum maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and lowers the price target from $41 to $40.
Needham analyst Gil Blum maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and lowers the price target from $41 to $40.